Variant t(2;18) translocation in a Burkitt conversion of follicular lymphoma

Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association·2026

Novel lipid nanoparticle in a mRNA cancer vaccine drives tumor control via type I IFNs and effector CD8+ T cells.

Molecular therapy. Nucleic acids·2026

Emerging biomarkers of immune checkpoint inhibitor toxicity in triple-negative breast cancer: a mini-review.

Frontiers in immunology·2026

Durable immunovirological control after sequential mogamulizumab and tucidinostat in relapsed or refractory adult T-cell leukemia/lymphoma.

Frontiers in immunology·2026

Generation of an NG2 targeting bispecific antibody for the induction of T-cell immunity against melanoma.

Journal of translational medicine·2026

Differential peripheral immune dynamics underlie therapeutic response to chemotherapy and chemoimmunotherapy in triple-negative breast cancer.

ImmunoHorizons·2026

Related Experiment Videos

Variant t(2;18) translocation in a Burkitt conversion of follicular lymphoma

Related Concept Videos

Translocation (14;19)(q32;q13.1) in a Young Patient who Developed a Large Cell Lymphoma after an Initial Diagnosis of CLL.

Two Translocations: a Follicular Variant 2; 18 and a Burkitt 8;14 in a Small Non Cleaved Non Hodgkin's Lymphoma.

Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML.

Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group.

CALM/AF10-positive leukemias show upregulation of genes involved in chromatin assembly and DNA repair processes and of genes adjacent to the breakpoint at 10p12.

Breakpoints of 11q25 in three similar cases of B non Hodgkin's lymphoma.

Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial.

Carrying a crisis: The risk of a painful sickle cell crisis during pregnancy.

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia-Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups.

Hyperdiploid multiple myeloma: A heterogeneous entity requiring refined risk stratification-Insights from chromosome count and cytogenetic abnormalities.

A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial.

Interplay between fibroblast growth factor 9 (FGF9) and CD44 underlies 46,XY disorders of sex development in Kruppel-like factor 1 (KLF-1)-E325K-associated congenital dyserythropoietic anaemia (CDA-IV).

Computed tomographic Characteristics of Presumed Normal Canine Iliosacral Lymph Nodes.

Novel lipid nanoparticle in a mRNA cancer vaccine drives tumor control via type I IFNs and effector CD8+ T cells.

Emerging biomarkers of immune checkpoint inhibitor toxicity in triple-negative breast cancer: a mini-review.

Durable immunovirological control after sequential mogamulizumab and tucidinostat in relapsed or refractory adult T-cell leukemia/lymphoma.

Generation of an NG2 targeting bispecific antibody for the induction of T-cell immunity against melanoma.

Differential peripheral immune dynamics underlie therapeutic response to chemotherapy and chemoimmunotherapy in triple-negative breast cancer.

Related Experiment Videos

Variant t(2;18) translocation in a Burkitt conversion of follicular lymphoma

Related Concept Videos

Related Articles